Background: People with head and neck cancer have higher comorbidity levels but it remains unclear if pretreatment comorbidity is an independent prognosticator in head and neck cancer. Methods: Survival analyses were performed using data from participants in a UK multicentre cohort study with cancers of the oral cavity (n = 668), oropharynx (n = 1074), and larynx (n = 530). Survival analyses were incrementally adjusted for age, sex, marital status, income, education, stage, alcohol, and smoking. Results: After adjusting for demographic, clinical, and behavioral confounders, higher baseline comorbidity was associated with reduced overall survival (mild comorbidity HR = 1.4, 95% CI = 1.1, 1.7; moderate comorbidity HR = 1.7, 95% CI = 1.3, 2.2; severe comorbidity HR = 2.8, 95% CI = 1.9, 4.; P-trend<.001). Conclusions: Our findings suggest that comorbidity is an independent prognosticator for overall survival in head and neck cancer. Comorbid illnesses should be considered in the assessment and treatment planning of people with head and neck cancer.
Comorbidity, the presence of coexistent medical conditions that are unrelated to the index disease, 3 may independently affect health outcomes. Higher comorbidity scores have been shown to be adversely associated with overall survival (OS), [3] [4] [5] [6] [7] choice of treatment modality, 3, 4, 8 and treatment outcomes in head and neck cancer. 5, [8] [9] [10] [11] People with head and neck cancer tend to have a higher comorbidity burden compared to the general population. 3, 6 This may partially be attributable to their engagement in adverse health behaviors such as smoking and high alcohol intake that increase the risk of the development of comorbid conditions as well as head and neck cancer. The classical risk factors for most head and neck cancers, with exception of thyroid and salivary gland tumors, are smoking and to a lesser extent alcohol consumption. More recently, the oncogenic human papillomavirus (HPV) has been shown to play a role in the development of certain head and neck cancer subtypes, specifically oropharyngeal squamous cell carcinomas. HPV-positive head and neck cancers differ from tobacco-related HPV-negative tumors in their clinical characteristics and risk factor profiles. 4, 12, 13 HPVpositive cancers typically present as smaller tumors with more frequent lymph node involvement but better OS. 13 These findings may be partially due to a more favorable risk factor profile. People with HPV-positive oropharyngeal tumors tend to be nonsmokers, consume less alcohol, have a higher socioeconomic status and a lower comorbidity burden. 4, 7, 12, 14 Previous studies have examined the impact of comorbidities on outcomes in head and neck cancer. 6, 7, [14] [15] [16] However, no prospective study has been able to adjust for HPV status, behavioral, and social variables in their study populations while stratifying for head and neck cancer subsite in the same model. Hence, there is insufficient evidence to conclude whether comorbidity burden at diagnosis is an independent prognostic indicator in people with head and neck cancer or whether it constitutes a surrogate marker for health risk behaviors. 4, 7 Despite these limitations, the evidence suggests that comorbidity may be a useful tool to help stratify people. Revised staging models that incorporate comorbidity index scores have been proposed. 4, 7 These models suggest that comorbidity in combination with the traditional TNM stage may be more accurate in predicting survival and could play an important role in treatment planning. Using data from Head and Neck 5000, a large UK multicentre prospective cohort study, we examined the relationship between comorbidity and outcomes in head and neck cancer. The objectives of this study were to analyze the relationship between comorbidity at diagnosis and OS before and after adjustment for confounders and at different sites.
| PATIENTS AND METHODS

| Study population
We used data from Head and Neck 5000, a large UK-based clinical cohort study that enrolled 5478 eligible participants of 11 158 eligible people with head and neck cancer between April 2011 and December 2014. 17 Research nurses or another trained member of the research team obtained informed written consent from all participants prior to study enrolment. 18 The South WestFrenchay Regional Ethics Committee granted full ethical approval (ref: 10/H0107/57) for Head and Neck 5000 in 2010. In addition, the research and development departments of each participating NHS Trust approved the study. Study methods and recruitment rates have previously been described in detail. 17, 18 For this study, we included White participants with head and neck cancer of the oral cavity, oropharynx, and larynx who were treated with curative intent (Figure 1 ).
| Comorbidity measure
The Adult Comorbidity Evaluation 27 (ACE 27) 19 was used to collect comorbidity data at diagnosis. The presence and severity of medical comorbidities were extracted from medical notes by local research nurses and scored by clinicians. Newly diagnosed head and neck cancers were excluded from the score. The final ACE 27 score was derived from the highest ranked comorbidity. Participants without comorbid conditions received a score of 0. Mild comorbidity was defined as an ACE 27 grade of 1. In cases where moderate decompensation (grade 2) was present in two or more conditions affecting different organ systems, a final grade of 3 (severe decompensation) was awarded.
| Measures of confounders
Confounding variables were identified based on previously reported associations with both exposure (comorbidity) and outcome (survival 
| Outcome measure
Study participants were flagged up with the UK Health and Social Care Information Centre for notification of date and cause of death. Survival time was measured from study enrolment until either death or the end of the most recent follow-up period.
| Statistical analysis
Chi-squared tests were used to assess the univariate relationship between categorical variables and comorbidity. Unadjusted Kaplan-Meier graphs were plotted to estimate OS for each cancer site. Cox proportional hazards regression models were used to evaluate OS in multivariable analyses. Hazard ratios (HR) and 95% confidence intervals (CIs) were adjusted for known or suspected confounders. Using the previously described confounding variables, four a priori survival models were incrementally fitted for each cancer site. Model 1 (Minimally adjusted) was adjusted for age and sex only. Model 2 (Clinical) included the same variables as Model 1 and also adjusted for TNM stage, treatment modality, and cancer site. Model 3 (Social) included all previously used variables plus marital status, annual household income, and education. Finally, Model 4 (Behavioral) was an extension of Model 3 with addition of smoking status and alcohol intake to the list of confounders. To test the proportional hazards assumption, scaled Schoenfeld residuals were applied. To investigate the association between HPV status and comorbidity stratified survival analyses were performed. Comorbidity was grouped into low (0-1) and high (≥2) ACE 27 scores to achieve a larger sample size for each category in HPV-stratified survival analyses.
Similarly, treatment-stratified analyses were performed to examine the relationship between surgical and nonsurgical treatment modalities and survival in people with different comorbidity burden. Surgical treatment was defined as surgery alone and surgery plus an adjunct therapy. Nonsurgical treatment modalities consisted of chemoradiation and stand-alone radiotherapy. The Head and Neck 5000 dataset version 2.2 was used for this study. All statistical analyses were performed using Stata 14.0 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, Texas: StataCorp LP).
| RESULTS
| Distribution of comorbidity in the study population
Complete data were available for 2272 participants. HPV data were available for a subset of oropharyngeal cancer (n = 932). A total of 466 deaths were recorded in 7167.9 person-years of follow-up. Mean follow-up time was 3.2 years (SD 1.2). Table 1 shows the baseline characteristics of study participants by cancer site. Almost half (52.6%) of the participants had at least one medical condition at the time of diagnosis. Participants with oropharyngeal cancers were more likely to have no comorbidity (52.5%) compared to participants with oral cavity (45.5%) or laryngeal cancers (39.5%). HPV serology was available for 86.8% (n = 932) of oropharyngeal cancer cases with HPV-positive cancers displaying a lower comorbidity burden than HPV-negative cancers. Ninety percent of oral cavity cancer cases were managed surgically compared with only 30.6% of oropharyngeal and 29.4% of laryngeal cancers (Table 1) . Univariate analyses showed that all covariates were individually associated with comorbidity (Table 2) . Participants' age (χ 2 = 138.4; df(3); P < 0.001), treatment modality (χ 2 = 124.3; df(9); P < .001) and annual household income (χ 2 115.1; df(6); P < .001) exhibited the strongest statistical evidence of an association with comorbidity burden. To explore the relationship further, treatment modality was grouped into surgical and nonsurgical modalities and the highest comorbidity scores (ACE >1) combined into one group. In this analysis, observed differences were small (49% of people with ACE = 0 had surgery compared to 47% of people with ACE >1) and there was no statistical evidence to support an association between surgical treatment and comorbidity (χ 2 = 3.42; df(2); P = .18; Cramer's V = 0.04).
With the exception of sex, education level and treatment modality, all covariates were also individually associated with OS (Supporting Information Table 1 ).
| Survival analyses
In a minimally adjusted Cox regression model comorbidity displayed a dose-dependent relationship with OS across all three head and neck cancer sites (Table 3) . After full adjustment for demographic, clinical, social, and behavioral factors, this trend remained strong with HRs of 1.4 (95% CI = 1.1, 1.7), 1.7 (95% CI = 1.3, 2.2), and 2.8 (95% CI = 1.9, 4.0) for mild, moderate, and severe comorbidity, respectively (P-trend<.001). In unadjusted Kaplan-Meier analyses, participants with oropharyngeal and oral cavity cancers who did not have comorbid conditions displayed the best survival, whereas for laryngeal cancers there was no clear survival benefit between participants without comorbidity and those with mild decompensation (Figure 2 ). The association between survival and comorbidity did not differ between HPV-positive and HPV-negative oropharyngeal cancers after adjusting for all covariates (Table 3) . Finally, fully adjusted and stratified survival analyses demonstrated that higher comorbidity was associated with worse OS in both people who received surgical treatment (HR = 1.6, 95% CI = 1.1, 2.2 for mild comorbidity; HR = 2.0, 95% CI = 1.4, 2.9 for moderate/severe comorbidity) and those who were managed with chemoradiation or radiotherapy alone (HR = 1.3, 95% CI = 0.9, 1.7 for mild comorbidity; HR = 1.8, 95% CI = 1.3, 2.5 for moderate/ severe comorbidity) ( Table 4 ). There was no statistical evidence of a difference in the association between comorbidity and survival in these two treatment groups. Schoenfeld residuals testing confirmed the validity of the proportional hazards assumption for all variables.
| DISCUSSION
In this large contemporary clinical cohort of people with head and neck cancer in the UK, we showed a doseresponse relationship between comorbidity and survival that was consistent across tumor sites and independent of adjustment for lifestyle confounding factors. The dose-dependent effect of comorbid status on OS (HR = 1.5, 95% CI = 1.2, 2.0 for mild comorbidity; HR = 3.8, 95% CI = 2.6, 5.4 for severe comorbidity; P-trend<.001) was mildly attenuated after full adjustment for all covariates (HR = 1.4, 95% CI = 1.1, 1.7 for mild comorbidity; HR = 2.8, 95% CI = 1.9, 4.0 for severe comorbidity; P-trend<.001). The narrow CIs and the consistency across cancer sites mean our findings are unlikely to be the result of chance.
Our findings are consistent with previous studies that identified pretreatment comorbidity as an important independent prognosticator. [5] [6] [7] 10, 14, 16, [22] [23] [24] [25] Only a few of these previous studies were able to control for smoking and alcohol intake in their analyses 4, 22, 24, [26] [27] [28] and none adjusted for socioeconomic variables and health risk behaviors in the same model. Most of these studies only included people with oropharyngeal cancers. 22, [26] [27] [28] One large Canadian cohort study analyzed data from medical record review to explore the impact of baseline comorbidity on OS across four head and neck cancer subsites. 4 They used the claims-based Charlson comorbidity index (CCI) 29 to record comorbidity data retrospectively.
Unlike the ACE 27 (used in our analysis), the CCI does not quantify disease severity and includes fewer comorbid conditions. Both indices are validated for use in people with cancer but data and results derived from different comorbidity indices may differ significantly. 15, 28, 30, 31 In the UK, the ACE 27 remains the recommended tool for recording comorbidity data in people with cancer. 32 They reported that higher comorbidity scores were associated with greater allcause mortality in people with cancers of the oral cavity, larynx, and nasopharynx. They observed marked attenuation after adjustment for confounders and as a result concluded that comorbidity was a surrogate marker for health risk behaviors rather than an independent prognostic indicator.
The lack of attenuation of the association in our data may reflect the more accurate prospective collection of data on comorbidity and lifestyle confounders.
In keeping with previous research, our baseline data also showed a lower burden of comorbidity and better unadjusted OS in people with HPV-positive oropharyngeal cancers compared to HPV-negative cases. 4, 12, 13, 16, 22, 23, 33 In HPV-stratified analyses, the dose-response relationship between comorbidity and survival was less pronounced. However, point estimates indicated that greater comorbidity remained associated with worse survival, independent of HPV status. Adjustment for potential confounders resulted in only a slight attenuation of the effect size in people with HPV-positive cancer and did not markedly change the observed association in people with HPVnegative cancers.
There is some evidence to suggest that comorbidity at diagnosis may influence treatment selection and may constitute an independent risk factor for postsurgical outcomes 3,9,10,34 and cause-specific mortality 35, 36 in people with head and neck cancer. However, these findings are not consistent throughout the literature with one study failing to demonstrate an association between concurrent comorbid conditions and survival in treatment-stratified analysis. 37 To date no prospective study has examined potential differences in baseline comorbidity scores and OS in people treated surgically compared to those who underwent conservative management for head and neck cancer. In our large cohort, the distribution of treatment modalities among cancer subsites reflects current standard of care. [38] [39] [40] [41] Oral cavity cancers were predominantly managed surgically whereas over two-thirds of oropharyngeal and laryngeal cancers received nonsurgical treatment. In univariate analysis, treatment modality was independently associated with comorbidity. However, the observed differences were modest suggesting that comorbid status is not an important determinant of treatment selection. When adjusted for potential confounders including cancer site, the OS of people who received surgical vs nonsurgical treatment were comparable. Our robust effect size estimates suggest that comorbidity is an important independent predictor of post-treatment survival irrespective of treatment modality.
| Implications for practice
In recent years, research suggested that presence of comorbid conditions may have a similar prognostic significance to increasing the stage of the cancer. 4, 5, 14, 42 Our results confirm the importance of comorbidity and support the use of pretreatment comorbidity data as part of a comprehensive prognostic assessment at the time of diagnosis. We also demonstrated that treatment selection does not affect the prognostic value of comorbidity burden. In the UK, the National Cancer Intelligence Network recommends that comorbidity data are collected for all people with cancer using the ACE 27 index to optimize preoperative assessment and risk stratification. 32 More research is needed to quantify the effect of specific conditions compared to total comorbidity burden on treatment outcomes to develop a comprehensive prognostic assessment system that combines TNM stage and comorbidity to more accurately predict survival in people with head and neck cancer.
| Strength and limitations
Our study has a number of strengths. First, this large prospective clinical cohort study with a sample size of 2272 participants allowed us to produce robust effect size estimates and stratify by cancer subsite. Second, we used the ACE 27 to document the presence and severity of comorbidity. Third, our analyses accounted for a broad range of known confounders in incrementally adjusted regression models. To date, no other study on the prognostic impact of comorbidity in head and neck cancer subtypes adjusted for clinical, socioeconomic, and behavioral covariates in the same model. This study therefore adds significantly to the emerging evidence on the importance of comorbidity as an independent prognostic indicator in head and neck cancer.
Our study also had some limitations. First, our list of confounding variables was extensive but it was not exhaustive. For example, anemia at diagnosis and performance status has been reported as potential predictors of survival in people with head and neck cancer 6, 9, 16, 35, 43, 44 but were not collected in our study. Types and details of comorbid conditions were not recorded. As a result, their distribution, individual association with the chosen treatment modality could not be analyzed. Second, we used self-report from questionnaires to collect information on health behaviors. Self-report may be unreliable and underestimate current behavior and not reflect prior or subsequent lifestyle behavior. Reassuringly, the proportion of current, former, and never smokers in this study was similar to that reported in other cohorts. 22, 24, 45 So, though we adjusted for a wide range of confounders in our models, residual confounding by unmeasured or poorly measured factors is still a possibility. Third, cause-specific mortality data were not available so we were unable to examine the association of comorbidity with specific causes of death. Fourth, despite a mean follow-up time of 3.2 years and the large overall sample size, the number of deaths and people with severe comorbidities was low in some groups, reducing statistical power in stratified analyses. Finally, only 49.1% of eligible people (n = 5478 of 11 158) were enrolled in the study and complete data were only available for less than half of all enrolled participants (n = 2272) limiting generalizability of our findings.
| Conclusion
Our study found that comorbidity at baseline is a strong prognostic indicator of survival in a subset of head and neck cancers, independent of health risk behaviors and treatment selection. Our findings support the need for comorbid disease to be included in future prognostication models for head and neck cancer to further aid treatment planning and to provide more accurate survival estimates.
